Clivatuzumab tetraxetan (IMMU107), a humanized anti-MUC1 monoclonal antibody, exhibits anti-tumor activity and holds potential for research in metastatic pancreatic cancer [1] [2].

Clivatuzumab tetraxetan (50, 100 µg; i.v.; once) effectively reduced tumor volume in a dose-dependent manner and extended the median survival of nude mice with Capan-1 tumors to 13 weeks. [2] Animal Model: Nude mice (Capan-1 tumors) [2] Dosage: 50, 100 µg Administration: I.v.; once Result: Significantly decreased tumor volume in a dose-dependent manner and increased the median survival to 13 weeks.